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A B S T R A C T
Background
Delirium is a common clinical syndrome defined as alterations in attention with an additional disturbance in cognition or perception,
which develop over a short period of time and tend to fluctuate during the course of the episode. Delirium is commonly treated
in hospitals or community settings and is often associated with multiple adverse outcomes such as increased cost, morbidity, and
even mortality. The first-line intervention involves a multicomponent non-pharmacological approach that includes ensuring effective
communication and reorientation in addition to providing reassurance or a suitable care environment. There are currently no drugs
approved specifically for the treatment of delirium. Clinically, however, various medications are employed to provide symptomatic
relief, such as antipsychotic medications and cholinesterase inhibitors, among others.
Objectives
To evaluate the effectiveness and safety of cholinesterase inhibitors for treating people with established delirium in a non-intensive care
unit (ICU) setting.
Search methods
We searched ALOIS, which is the Cochrane Dementia and Cognitive Improvement Group’s Specialised Register, on 26 October 2017.
We also cross-checked the reference lists of included studies to identify any potentially eligible trials.
Selection criteria
We included randomised controlled trials, published or unpublished, reported in English or Chinese, which compared cholinesterase
inhibitors to placebo or other drugs intended to treat people with established delirium in a non-ICU setting.
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Data collection and analysis
We used the standard methodological procedures expected by Cochrane. The primary outcomes were duration of delirium, severity
of delirium, and adverse events. The secondary outcomes were use of rescue medications, persistent cognitive impairment, length
of hospitalisation, institutionalisation, mortality, cost of intervention, leaving the study early, and quality of life. For dichotomous
outcomes, we calculated the risk ratio (RR) with 95% confidence intervals (CIs); for continuous outcomes we calculated the mean
difference (MD) with 95% CIs. We assessed the quality of evidence using GRADE to generate a ’Summary of findings’ table.
Main results
We included one study involving 15 participants from the UK. The included participants were diagnosed with delirium based on the
Confusion Assessment Method (CAM) criteria. Eight males and seven females were included, with a mean age of 82.5 years. Seven of
the 15 participants had comorbid dementia at baseline. The risk of bias was low in all domains.
The study compared rivastigmine with placebo. We did not find any clear differences between the two groups in terms of duration
of delirium (MD -3.6, 95% CI -15.6 to 8.4), adverse events (nausea, RR 0.30, 95% CI 0.01 to 6.29), use of rescue medications
(RR 0.13, 95% CI 0.01 to 2.1), mortality (RR 0.10, 95% CI 0.01 to 1.56), and leaving the study early (RR 0.88, 95% CI 0.07 to
11.54). Evidence was not available regarding the severity of delirium, persistent cognitive impairment, length of hospitalisation, cost
of intervention, or other predefined secondary outcomes.
The quality of evidence is low due to the very small sample size.
Authors’ conclusions
There is insufficient evidence to support or refute the use of cholinesterase inhibitors for the treatment of delirium in non-ICU settings.
No clear benefits or harms associated with cholinesterase inhibitors were observed when compared with placebo due to the lack of data.
More trials are required.
P L A I N L A N G U A G E S U M M A R Y
Cholinesterase inhibitors for people with delirium, not including those in intensive care units
Background
During a period of illness, people can develop symptoms of confusion and altered consciousness, which is known as delirium. Compared
to patients with no delirium, patients with delirium spend a longer time in hospital and are less likely to survive their illness. Treatment
of delirium should focus on good care of the underlying illness and strategies such as reorientation of the patient. However, medication-
based treatments are still often used. Medications used for treating the symptoms of dementia (cholinesterase inhibitors) may have a
role in treating delirium.
Review question
We wished to find out if treatment with a cholinesterase inhibitors reduces the severity or duration of delirium. We were also interested
in side effects from cholinesterase inhibitors. Delirium is often seen in severe illnesses that require high levels of medical and nursing
care, for example in the intensive care unit. In this review we focused on studies of patients who were not in a high-level care setting.
Study characteristics
We found one trial from the UK, which included 15 participants with delirium. The average age of the participants was 82.5 years;
eight participants were male and seven were female. Seven participants also had a history of dementia. This trial compared rivastigmine
(a type of cholinesterase inhibitor used in the treatment of dementia) with an inactive treatment (placebo).
Key results
The trial did not show any difference in effect between those participants given rivastigmine and those given placebo. The study
was conducted and reported appropriately, but the small number of participants limits any conclusions that could be made about
rivastigmine as a treatment for delirium.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Cholinesterase inhibitors (rivastigmine) compared to placebo for the treatment of delirium in non- ICU settings
Patient or population: people with delirium
Settings: non-ICU
Intervention: cholinesterase inhibitors (rivast igmine)*
Comparison: placebo
Outcomes Illustrative comparative risks* * (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Cholinesterase in-
hibitors (rivastigmine)
Duration of delirium
days
Follow-up: 42 days
The mean durat ion was
9.9 days
The mean durat ion was
3.6 days lower
(15.6 lower to 8.4
higher)
Not est imable 15
(1 study)
⊕⊕©©
Low1
The data were reported
by Overshott 2010.
The study was grossly
underpowered, and the
data were skewed
Severity of delirium
CAM negative
Follow-up: 28 days
See comment See comment See comment See comment See comment No study reported this
outcome.
Adverse events
nausea
Follow-up: 42 days
143 per 1000 43 per 1000
(1 to 899)
RR 0.3
(0.01 to 6.29)
15
(1 study)
⊕⊕©©
Low1
Persistent cognitive
impairment
See comment See comment See comment See comment See comment No study reported this
outcome.
Length of hospitalisa-
tion
See comment See comment See comment See comment See comment No study reported this
outcome.
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Mortality
Follow-up: 42 days
571 per 1000 57 per 1000
(6 to 891)
RR 0.1
(0.01 to 1.56)
15
(1 study)
⊕⊕©©
Low1
Cost of intervention See comment See comment See comment See comment See comment No study reported this
outcome.
* The dose of intervent ion: 1.5 mg once a day increasing to 1.5 mg twice a day af ter 7 days
* * The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CAM: Confusion Assessment Method; CI: conf idence interval; ICU: intensive care unit ; RR: risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality:We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of ef fect, but there is a possibility that it is substant ially
dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded twice for imprecision due to very small sample size.
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B A C K G R O U N D
This review supersedes a previous Cochrane Review,
’Cholinesterase inhibitors for delirium’, which was first published
in Issue 1, 2008 (Other published versions of this review).
Description of the condition
Delirium is a common clinical syndrome characterised by alter-
ations in attention and additional disturbances in cognitive func-
tion or perception, which has an acute onset and a fluctuating
course (APA 2013).
Delirium is a neuropsychiatric disturbance with multiple aetiolo-
gies and can be the consequence of a medical condition, sub-
stance intoxication or withdrawal, or exposure to a toxin (APA
2013). The causes of delirium are multifactorial and include pa-
tient vulnerability factors (such as dementia or cognitive impair-
ment, ageing, medical comorbidity, malnutrition, history of alco-
hol abuse and prescription opioid or benzodiazepine use, among
others) and potentially modifiable factors (such as infections, de-
hydration, electrolyte abnormalities, polypharmacy, seizures, and
surgery) (Inouye 2014; Vasilevskis 2012). The core symptoms of
delirium include altered levels of attention and awareness that typ-
ically develop over a short period of time and represent a change
from the patient’s baseline level of attention and awareness. These
alterations may fluctuate in severity throughout the course of the
episode, at times worsening in the evening and overnight (APA
2013; Schwartz 2016). People with delirium experience increased
mortality, postoperative complications (Raats 2015), readmissions
(McKhann 2002), poorer functional outcomes (Inouye 1998),
risk of dementia (Davis 2012), length of hospital stay (McCusker
2003), and higher healthcare expenditures (Leslie 2008).
Delirium can manifest as hyperactivity, hypoactivity, or mixed
(when both hypoactive and hyperactive features are present)
(NICE 2014). The fifth edition of the American Psychiatric As-
sociation’s Diagnostic and Statistical Manual of Mental Disorders
(DSM-V) and the 10th Revision of the International Classifica-
tion of Diseases (ICD-10) provide the current standard reference
diagnostic criteria (APA 2013; WHO 1993). Over the years, vari-
ous diagnostic and screening instruments have been developed for
making the diagnosis of delirium based on the DSM criteria, and
these have been used or adapted in various research and clinical
applications (Grover 2012; Oh 2017). The Confusion Assessment
Method (CAM), which provides a simple diagnostic algorithm,
is widely used for identification of delirium worldwide (Hshieh
2018). The 4AT, a new widely used instrument for rapid delirium
screening, is also easy and brief to administer and has high sensi-
tivity and specificity (Bellelli 2014; De 2017).
The highest incidence rates of delirium are noted in intensive care
unit (ICU) settings, reaching up to 80% (Marcantonio 2017). The
incidence of postoperative delirium varies depending on the type
of surgical procedure. For example, rates of 12% to 50% have been
reported after non-cardiac surgery (Brouquet 2010; Olin 2005;
Shah 2012), up to 51% after cardiac surgery (Smulter 2013), and
12% to 61% after orthopaedic operations (Holmes 2000). The
incidence of delirium in palliative care settings ranges from 3%
to 45% (Perrar 2013). In general medical and geriatric medicine
wards, incidence rates range from 11% to 29% (Inouye 2014).
The prevalence of deliriumon admission to these wards is also high
(18% to 35% in general medical wards) (Inouye 2014). When
combined with the incidence rates of newly occurring delirium
after admission, the overall occurrence of delirium in these set-
tings is relatively high. The epidemiology of delirium in emer-
gency departments is not as well established (Vasilevskis 2012).
Furthermore, delirium is not exclusive to hospital settings. One
study found an incidence of delirium of 20% in nursing home
residents who experience an acute illness (Flaherty 2013).
The ICU is an organised system that provides intensive and spe-
cialised medical and nursing care. Patients in ICU settings appear
to have different characteristics when compared with patients in
other settings. For example, patients in the ICU are more critically
ill than patients in other settings. Treatment priorities also tend
to be different. Medical treatment in the ICU focuses on multiple
modalities of physiologic organ support to sustain life during a
period of acute organ system insufficiency (Marshall 2017). Po-
tential clinical heterogeneity can therefore be expected between
ICU and non-ICU settings. This review complements a review on
delirium in ICU settings that is being performed by the Cochrane
Anaesthesia Group (Greve 2012).
Description of the intervention
The treatment of delirium aims to enhance recovery, maximise
functional status, and improve clinical outcomes. In addition to
general symptomatic management, a key element of management
is the investigation and treatment of any reversible underlying
causes (Schwartz 2016; Young 2010). According toNational Insti-
tute for Health and Care Excellence (NICE) guidance, multicom-
ponent non-pharmacological approaches are used as a first-line
intervention for the treatment of delirium in adults. This strategy
includes ensuring effective communication and reorientation (e.g.
explaining where the person is, who they are, and what your role
is), providing reassurance to people diagnosed with delirium, in-
volving family, friends, and caregivers to help in this process, and
providing a suitable care environment (NICE 2014). There are
currently no drugs specifically approved by the US Food and Drug
Administration (FDA) or other medicine licensing bodies to treat
delirium. In practice, however, clinicians currently employ various
medications for symptomatic relief (Breitbart 2012; NICE 2014).
Antipsychotic medications are often used for the treatment of
delirium. This is especially true for second-generation antipsy-
chotic drugs, which,when comparedwith first-generation antipsy-
chotic drugs (such as haloperidol), require a shorter time to take
effect and produce fewer extrapyramidal symptoms (Kishi 2016).
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According to the NICE guidelines, if a person is distressed or
presents a substantial risk to themselves or others, antipsychotic
drugs (olanzapine or haloperidol) are not recommended for the
treatment of delirium unless non-pharmacological measures have
been ineffective or inappropriate (NICE 2014). Benzodiazepines
play a role in the treatment of delirium caused by withdrawal from
sedatives or alcohol. However, they are not useful in the treatment
of delirium from other causes because they can cause confusion
and drowsiness, particularly in the elderly (Catic 2011). Some re-
search has demonstrated that dexmedetomidine, an α2-adreno-
ceptor agonist, is useful in the treatment of delirium associated
with cancer pain, surgery, or alcohol withdrawal (Ayeko 2015;
Nguyen 2016). Though cholinesterase inhibitors such as rivastig-
mine, donepezil, and galantamine have been used to treat delir-
ium, evidence regarding their effectiveness is inconsistent. One
randomised controlled trial found that rivastigmine, when added
to standard treatment with haloperidol, potentially increased the
severity of delirium as well as mortality in people in the ICU (van
Eijk 2010). However, other primary prospective studies (non-ran-
domised) suggested that rivastigmine was useful for delirium as-
sociated with Alzheimer’s disease, vascular dementia, or stroke in
non-ICU settings (Litvineneko 2010;Oldenbeuving 2008).Other
cholinesterase inhibitors such as donepezil have also been studied
for the prevention of delirium (Liptzin 2005; Marcantonio 2011;
Sampson 2007).
How the intervention might work
Themechanisms underlying the development of deliriumare com-
plex and poorly elucidated, though several theories have been pro-
posed (Maldonado 2008). One of the leading hypotheses is that
delirium results from an impairment of central cholinergic trans-
mission, considered by some investigators to be ’a common de-
nominator’ in this disorder (Blass 1981). Acetylcholine is themain
neurotransmitter that mediates learning and attention, functions
that are profoundly disturbed during delirium. Impaired cholin-
ergic function also correlates with the cognitive and behavioural
changes observed in people with delirium (Trzepacz 1996). Fur-
thermore, drugs with anticholinergic effects may induce delir-
ium, while cholinergic drugs can improve delirium induced by
lithium and anticholinergic medications (Oldenbeuving 2008).
By inhibiting the activity of the enzymes that metabolise acetyl-
choline, cholinesterase inhibitors cause increased cholinergic ac-
tivity at synapses (Masuda 2015). They have also been shown to
play a role in improving cognitive function in people with de-
mentia (Chen 2016; Li 2015; Rolinski 2012). Both delirium and
dementia share cholinergic deficiency as a mechanistic hypothesis
(Hshieh 2008; Wang 2009). The three cholinesterase inhibitors,
rivastigmine, donepezil, and galantamine, are currently approved
as first-line drugs for the treatment of dementia associated with
Alzheimer’s disease (Li 2015; Qaseem 2008), and are also recom-
mended by NICE for the treatment of Lewy body diseases (i.e. de-
mentiawith Lewybodies andParkinson’s disease dementia) (NICE
2011). By treating the presumed cholinergic deficiency in people
with delirium, acetylcholinesterase inhibitors may therefore have
beneficial effects.
Why it is important to do this review
This review supersedes the previous review ’Cholinesterase in-
hibitors for delirium’, which was published in 2008 (Other
published versions of this review). That review included only one
trial, Liptzin 2005, which compared donepezil with placebo for
the prevention and treatment of postoperative delirium in people
over the age of 50 without dementia who were undergoing elective
total joint replacement. More studies have since been conducted
with various cholinesterase inhibitors in different settings. Com-
pared with patients in non-ICU settings, patients in the ICU have
a higher risk of delirium. In addition, different validation delir-
ium assessment instruments and treatment strategies are employed
in the management of ICU patients (Hayhurst 2016; Oh 2017).
Since delirium in ICU settings as a sole scope has been examined
in previous reviews (Hayhurst 2016; Trogrli 2015), this review
focused on cholinesterase inhibitors for the treatment of delirium
in non-ICU settings.
O B J E C T I V E S
To evaluate the effectiveness and safety of cholinesterase inhibitors
for treating people with established delirium in a non-ICU setting.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We planned to include randomised controlled trials, published or
unpublished, which were reported in English or Chinese.
Types of participants
We planned to include participants over 16 years of age, of either
sex, diagnosed with delirium by standardised diagnostic criteria
(e.g. DSM-IV, DSM-V, ICD-10). If studies stated that people
had delirium but did not use standardised diagnostic criteria, we
planned to include these studies in the meta-analysis and conduct
sensitivity analyses to test whether the inclusion criteria influenced
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the results. We also planned to include participants who experi-
enced delirium from any cause (such as medical illnesses and ad-
verse effects frommedications) with the exception of alcohol/drug
withdrawal. We planned to include studies conducted in either
hospital or community settings. We excluded those studies that
explicitly mentioned that people were recruited in the ICU, re-
gardless of the type of ICU (such as general ICUs and other special
ICUs including coronary care units, trauma ICUs, etc.). However,
if the study described the setting as a high dependency unit where
patients were cared for more extensively than in a normal ward,
but not to the point of intensive care, we planned to include the
study.
Types of interventions
We planned to include trials assessing the effect of any of the cur-
rently marketed cholinesterase inhibitors (e.g. donepezil, rivastig-
mine, galantamine), administered at any dose and at any frequency,
compared with placebo. We also planned to include head-to-head
comparisons of a cholinesterase inhibitor with another drug in-
tended to treat delirium (e.g. antipsychotic drugs, α2-adrenocep-
tor agonists, benzodiazepines, and melatonin).
We also planned to include trials involving non-pharmacological
management strategies if we could extract data from the groups.
Types of outcome measures
Primary outcomes
• Response to treatment:
◦ duration of delirium;
◦ severity of delirium measured by validated scales (e.g.
Memorial Delirium Assessment Scale (MDAS) (Breitbart 1997),
Delirium Rating Scale (DRS) (Trzepacz 1988), or DRS-R-98
(Trzepacz 2001).
• Adverse events
Secondary outcomes
• Use of rescue medications (e.g. one-off doses of
antipsychotic drug)
• Persistent cognitive impairment (defined by original studies)
• Length of hospitalisation
• Institutionalisation
• Mortality
• Cost of intervention (such as direct monetary cost of
intervention to participants or healthcare services)
• Leaving the study early
• Quality of life
Search methods for identification of studies
Electronic searches
We searched
ALOIS (www.medicine.ox.ac.uk/alois), the Cochrane Dementia
and Cognitive Improvement Group’s Specialised Register, on 26
October 2017.
ALOIS is maintained by the review group’s Information Specialist
and contained dementia and cognitive improvement studies iden-
tified from:
• quarterly search of the Cochrane Central Register of
Controlled Trials (CENTRAL);
• monthly searches of major healthcare databases:
MEDLINE, Embase, CINAHL (Cumulative Index to Nursing
and Allied Health Literature), PsycINFO, and LILACS (Latin
American and Caribbean Health Sciences Literature);
• monthly searches of trial registers: metaRegister of
Controlled Trials (www.isrctn.com/page/mrct); UMIN Clinical
Trials Registry (www.umin.ac.jp/ctr/); World Health
Organization International Clinical Trials Registry Platform (
apps.who.int/trialsearch) (which covers ClinicalTrials.gov,
ISRCTN, Chinese Clinical Trials Register, German Clinical
Trials Register, Iranian Registry of Clinical Trials, and the
Netherlands National Trials Register, plus others);
• monthly searches of a grey literature source: ISI Web of
Science Core Collection.
To view a list of all sources searched for ALOIS please see About
ALOIS.
We ran additional searches to ensure we had retrieved the most
up-to-date results. The search strategies used for the retrieval of
reports of trials from bibliographic databases and trial registries
can be seen in Appendix 1.
Searching other resources
We cross-checked the reference lists of included studies to identify
any potentially eligible trials.
Data collection and analysis
Selection of studies
Two review authors (AY and SW) independently assessed each ab-
stract and title for relevance.We obtained the full texts of citations
that described a potentially relevant randomised controlled trial
for further assessment. Two review authors independently deter-
mined eligibility of these trials for inclusion. Any disagreements at
any stage of the study selection process were resolved by discussion
or by the involvement of a third review author (ZZ).
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Data extraction and management
Two review authors (AY and SW) independently extracted data
using prespecified data extraction forms. A pilot data extraction
was performed before the formal data extraction. Any discrepan-
cies were resolved by discussion. We collected the following infor-
mation where possible.
Participant characteristics
• Age
• Sex
• Education
• Diagnostic criteria for delirium
• Severity of delirium
• Underlying aetiology of delirium
• Baseline comorbid dementia
• Setting (refers to the environment where the clinical trial
was conducted, e.g. palliative care settings, general or geriatric
wards, emergency departments)
• Inclusion or exclusion criteria of the original studies
Intervention characteristics
• Types of cholinesterase inhibitors
• Description of the comparator
• Dose, route, frequency, and duration of cholinesterase
inhibitor and comparator
• Duration of treatment
• Any concomitant treatments
Outcomes
• Outcomes as outlined in Types of outcome measures
• Definition, instruments, and measured time points of
outcomes
Methodological characteristics
• Sample size
• Duration of follow-up
• Information needed for ’Risk of bias’ assessment
For continuous data, we extracted the mean, standard deviation,
and number of participants for each treatment group at each time
point, if available. For dichotomous data, we retrieved the number
in each treatment group and numbers experiencing the outcome of
interest where possible. If only treatment effects and their standard
errors were reported, these would be extracted.
Assessment of risk of bias in included studies
Two review authors (AY and SW) independently assessed the
risk of bias of each included study using the Cochrane ’Risk
of bias’ tool (Higgins 2011), which evaluates the following risk
domains: random sequence generation; allocation concealment;
blinding of participants, personnel, and outcome assessors; incom-
plete outcome data; selective outcome reporting; and other po-
tential sources of bias (including source of financial support). We
used the criteria reported in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). We applied the following
judgements to each domain: low risk, high risk, or unclear risk
(either lack of information or uncertainty over the potential for
bias). Any disagreements were resolved by consensus or by con-
sulting a third review author (ZZ) when necessary.
Measures of treatment effect
If trials used the same rating scale to assess the outcome,we planned
to calculate the mean difference (MD) with a 95% confidence in-
terval (CI); if different rating scales were used to measure the same
outcome, we planned to employ the standardised mean difference
(SMD) for continuous data. The treatment effect for dichotomous
outcomes was expressed as a risk ratio (RR) with a 95% CI.
Unit of analysis issues
For studies with multiple eligible treatment groups, we planned
to use one of the approaches described in Section 16.5.4 of the
Cochrane Handbook for Systematic Reviews of Interventions to over-
come the unit of analysis error (Higgins 2011). Our preferred ap-
proach was to merge all relevant experimental intervention groups
of the study into a single group and to merge all relevant control
intervention groups into a single control group. If this approach
was not suitable, we planned to include all relevant experimental
groups and split the shared control group.
Dealing with missing data
We planned to report missing outcome data and consider and
discuss the potential impact of themissing data on the results for all
outcomes. When attrition for a continuous outcome was between
0% and 50%, and only data from people who had completed the
study to that point were reported, we planned to reproduce these.
We anticipated that some studies would have used the method
of last observation carried forward (LOCF) or other imputation
methods. If less than 50% of the data had been imputed, we would
present and use these data and report the imputationmethod used.
For studies with more than 50% of imputed data, we would use
the data, but would conduct a sensitivity analysis by excluding
these studies to test the robustness of the result.
If standard deviations were not reported, we would first attempt
to obtain the missing values from the study authors. If this was not
possible, we would attempt to calculate standard deviations from
the available statistics in the study report according to the meth-
ods described in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011).
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Assessment of heterogeneity
Two review authors (AY and SW) independently assessed clinical
and methodology heterogeneity, and only planned on conducting
meta-analyses when the study quality, participants, interventions,
and outcomes were sufficiently similar. We planned on assessing
statistical heterogeneity using the I2 statistic (I2 greater than 50%
may represent substantial heterogeneity) combined with the P
value from the Chi2 test (P < 0.1), if a meta-analysis was to be
performed (Higgins 2011).
Assessment of reporting biases
If at least 10 studies were available for meta-analysis, we planned
on assessing the effect of publication bias using a funnel plot to
identify small-study effects.
Data synthesis
Weplanned on conductingmeta-analyses using theMantel-Haen-
szel method for dichotomous outcomes, and the inverse variance
method for continuous outcomes.We planned to use a random-ef-
fectsmodel for all analyses. For cases inwhich the statistical hetero-
geneity was significant (P value from Chi2 test < 0.1 and I2 greater
than50%),we planned to explore and address the source of hetero-
geneity as described in the Subgroup analysis and investigation
of heterogeneity section.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis
When data allowed, we planned to conduct a subgroup analysis
according to:
• participant age (older than 65 years versus 65 years or
younger);
• different causes of delirium (e.g. postoperative delirium,
adverse events to medication, or delirium due to hepatic
encephalopathy);
• presence or absence of pre-existing dementia or
neurocognitive impairment.
Investigation of heterogeneity
Where there was evidence of statistical heterogeneity (P value from
Chi2 < 0.1 and I2 greater than 50%) of the treatment effect be-
tween trials, if we could identify possible sources of variation,
we planned to explore the source of the heterogeneity and con-
duct subgroup analyses. Otherwise, we would use a random-ef-
fects model to pool the data. Where statistical heterogeneity was
significant in a meta-analysis, we would consider downgrading
the quality of evidence using the GRADE approach (GRADEpro
GDT 2015; Schünemann 2011a; Schünemann 2011b).
Sensitivity analysis
Where possible, we planned to conduct a sensitivity analysis to
explore the influence of the quality of trials by excluding data from
low-quality trials. We would define low-quality trials as those in
which more than 50% of the data in one arm of the study was
lost or studies with a high risk of selection bias and a high risk
of detection bias due to non-blind outcome assessment. We also
planned to conduct a sensitivity analysis to investigate the differ-
ence between results from completers-only and intention-to-treat
analysis (for primary outcomes only). We planned on presenting
results from both approaches separately and discussing the results
at the full review stage.
’Summary of findings’ table
For each comparison, we used the GRADE approach to assess the
quality of the body of evidence for all outcomes (GRADEproGDT
2015; Schünemann 2011a; Schünemann 2011b). We presented
the following results in the ’Summary of findings’ tables.
• Duration of delirium
• Severity of delirium
• Adverse events
• Persistent cognitive impairment
• Length of hospitalisation
• Mortality
• Cost of intervention
Evidence was given one of four possible ratings: high, moderate,
low, or very low quality. A rating of high quality indicated that
we were confident in our estimate of the effect and that further
research was very unlikely to change this, whereas a rating of very
low quality implied that we were very uncertain about the esti-
mate of the effect. TheGRADE approach rates evidence from ran-
domised controlled trials as high quality initially, however several
factors could lead to the downgrading of the evidence, namely:
study limitations (risk of bias); inconsistency; indirectness of ev-
idence; imprecision; and publication bias (Schünemann 2011a;
Schünemann 2011b).
R E S U L T S
Description of studies
See Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
We identified a total of 194 records from databases (164 records)
and other sources (30 records). The total number of records was
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unchanged after de-duplication. We excluded 164 records based
on the title and abstract. Of the remaining 30 records assessed in
full, we excluded 27 records with reasons (see Excluded studies).
One record is an ongoing study (NCT01487317). We eventually
included only one study (Overshott 2010, with two records) in
this review (see Figure 1 for more details).
Figure 1. Study flow diagram.
Included studies
Only one study with 15 participants that compared rivastig-
mine with placebo met the inclusion criteria for this review (see
Characteristics of included studies) (Overshott 2010).
The 15 participants were recruited from the UK and were diag-
nosed with delirium based on the Confusion Assessment Method
(CAM) criteria. Seven of the 15 participants had comorbid de-
mentia at baseline. The mean age of the participants was 82.5
years; eight participants were male and seven were female.
The study reported the following outcomes: duration of delirium
as assessed by CAM criteria, adverse events, use of rescue medi-
cations (additional psychotropic medications received), mortality,
and leaving the study early. Other predefined outcomes of this re-
view (severity of delirium, persistent cognitive impairment, length
of hospitalisation, institutionalisation, cost of intervention, and
quality of life) were not reported.
Excluded studies
See Characteristics of excluded studies.
We excluded a total of 27 studies from this review for the following
reasons.
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1. Twelve studies were not randomised controlled trials
(Chapin 1977; Dautzenberg 2004; Fischer 2001; Gleason 2003;
Granacher 1976; Heiser 1974; Hori 2003; Kaufer 1998;
Lankarani-Fard 2006; Listed 2011; Newman 1980; Scicutella
2015; Sheldon 2010; Wengel 1999).
2. Participants of nine studies did not have a diagnosis of
delirium in a non-ICU setting (EUCTR2007-000262-20-GB;
Crowell 1967; Doraiswamy 2007; Liptzin 2005; Marcantonio
2011; Moretti 2004; Silver 2006; Tenovuo 2009; Van Eijk 2010;
Youn 2017; Zaslavsky 2012).
3. We excluded one study due to the interventions being
evaluated (Pitkala 2006). This study compared an intensified,
multicomponent geriatric treatment group with a control group,
and we were unable to extract data from the groups that differed
only in terms of exposure to cholinesterase inhibitor versus
placebo.
4. One clinical trial was terminated with no published results
(NTR 537). We contacted the primary investigator, who
informed us that no data had been published from this trial.
Ongoing studies
See Characteristics of ongoing studies.
We identified one ongoing study begun in France in 2011
(NCT01487317). Though recruitment was complete, no results
have been reported or published. We planned to contact the pri-
mary investigator for more details but contact information was
not available.
Risk of bias in included studies
The summary of risk of bias in the included study is presented in
Figure 2 and Figure 3 (Overshott 2010). Please refer to the ’Risk of
bias’ table in Characteristics of included studies for further details.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
The included study stated that participants were randomised by
numbered treatment packets developed by the special statistics
department, which was independent of the research team. The
random sequence was concealed before allocation. We therefore
rated this study as at low risk of selection bias.
Blinding
The included study used a convincingly double-blinded design
that ensured blinding of both the participants and researchers.We
rated this study as at low risk of performance and detection bias.
Incomplete outcome data
Twoparticipants left the study early due to protocol violation.One
person in the rivastigmine group withdrew their consent when
CAM was negative for two consecutive days. One person in the
placebo group lost the trial medication after being transferred to
another ward. The number of dropouts was small and balanced
between the two groups. Given that the reasons for the dropouts
were not related to the intervention, we rated this study as having
a low risk of attrition bias.
Selective reporting
We did not obtain the protocol for this study. The study reported
all outcomes that were stated in the methods section, and the
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primary outcome in this review was reported as well. We rated the
study as at low risk of reporting bias.
Other potential sources of bias
We found no other obvious bias in the included study and rated
it as at low risk for this domain.
Effects of interventions
See: Summary of findings for the main comparison
Cholinesterase inhibitors (rivastigmine) compared to placebo for
the treatment of delirium in non-ICU settings
We included one study that involved 15 participants and com-
pared rivastigmine with placebo (Overshott 2010). The quality of
evidence for the reported outcomes was low due to the very small
sample size (see Summary of findings for the main comparison).
Primary outcomes
Response to treatment: duration of delirium
The study reported that the mean (standard deviation, range) du-
ration of delirium for participants in the rivastigmine and placebo
groups was 6.3 (5.7, 1 to 19) days and 9.9 (14.6, 1 to 42) days,
respectively. The mean and range of duration of delirium were
shorter for the rivastigmine group compared with the placebo
group, although the authors did not find a clear difference (mean
difference (MD) -3.6, 95% confidence interval (CI) -15.6 to 8.4;
Analysis 1.1) due to the very small sample size (lack of statistical
power).
The study used unpaired t-test for this outcome to measure MD.
However, we found that the data were skewed, and therefore a
parameter test was not applicable. Hence, we just presented the
results as other data in this review.
Response to treatment: severity of delirium
The study did not report this outcome.
Adverse events
Only one participant in the placebo group had nausea. The study
found no clear difference in the incidence of nausea between the
two groups (risk ratio (RR) 0.30, 95% CI 0.01 to 6.29; Analysis
1.2).
Secondary outcomes
Use of rescue medications
Three participants in the placebo group and no participants in
the rivastigmine group received additional psychotropic medica-
tion due to behavioural disturbances. The study found no clear
difference between the two groups (RR 0.13, 95% CI 0.01 to 2.1;
Analysis 1.3).
Persistent cognitive impairment
The study did not report this outcome.
Length of hospitalisation
The study did not report this outcome.
Institutionalisation
The study did not report this outcome.
Mortality
Four participants in the placebo group and no participants in the
rivastigmine group died. The study found no clear difference in
mortality between the groups (RR 0.10, 95% CI 0.01 to 1.56;
Analysis 1.4).
Cost of intervention
The study did not report this outcome.
Leaving the study early
One participant in the rivastigmine group and one participant in
the placebo group left the study early. The study found no clear
difference in withdrawals between the two groups (RR 0.88, 95%
CI 0.07 to 11.54; Analysis 1.5).
Quality of life
The study did not report this outcome.
Subgroup analysis
Wedid not perform any subgroup analysis due to insufficient data.
Sensitivity analysis
We did not perform any sensitivity analysis due to insufficient
data.
Assessment of reporting biases
Wedid not produce a funnel plot to assess reporting biases because
no meta-analysis included at least 10 studies.
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D I S C U S S I O N
Summary of main results
We identified only one study that compared a cholinesterase in-
hibitor with placebo for the treatment of delirium in non-ICU
patients. Based on the absolute difference, the duration of delir-
ium was shorter in the rivastigmine group (3.6 days on average)
compared with the placebo group, and no deaths occurred in
the rivastigmine group. However, this study had limited data (15
participants) with low-quality evidence. Any comparative analysis
would be unlikely to show an effect because the study was grossly
underpowered. Hence, in actuality we did not find any clear dif-
ferences in the duration of delirium, adverse events, use of rescue
medications, mortality, or the number of participants leaving the
study early. No evidence was available to evaluate severity of delir-
ium or the remaining secondary outcomes.
Overall completeness and applicability of
evidence
The overall completeness and applicability of the evidence in terms
of the participants, interventions, and outcomes were poor and
very limited in this one included study. For one, the included par-
ticipants were diagnosed with delirium using CAM rather than
the standardised diagnostic criteria (e.g. DSM-IV, DSM-V, ICD-
10). Patient demographics were also limited in terms of coun-
try of origin (all participants were from the UK) and age dis-
tribution (the average age was over 80 years). Rivastigmine and
placebo were the only interventions, and no other cholinesterase
inhibitor drugs (e.g. donepezil, galantamine) were evaluated. Fur-
thermore, there were no comparisons of a cholinesterase inhibitor
with other drugs intended to treat delirium such as antipsychotic
drugs, α2-adrenoceptor agonists, benzodiazepines, or melatonin.
A very small amount of data was reported on outcomes such as
duration of delirium, adverse events (nausea), use of rescue med-
ications, mortality, and leaving the study early. Most predefined
outcomes in this review were not reported, including the severity
of delirium, persistent cognitive impairment, length of hospital-
isation, institutionalisation, cost of intervention, and quality of
life. The applicability of this current evidence is therefore limited.
Quality of the evidence
The included study had a low risk of bias across all domains. We
downgraded the overall quality of evidence to low due to the very
small sample size.
Potential biases in the review process
We minimised the potential biases in the review process by per-
forming a thorough and complete search of the databases and
other sources. Two review authors (AY and SW) independently
screened and extracted the data using prespecified data extraction
forms, a process that lessens the likelihood of introducing bias in
the review process.
Agreements and disagreements with other
studies or reviews
This review supersedes a previous Cochrane Review that was orig-
inally published in 2008 (Other published versions of this review).
This latter review included one study that evaluated the possible
benefit of donepezil versus placebo in the prevention and treat-
ment of postoperative delirium in an elderly population with-
out dementia undergoing elective total joint replacement surgery
(Liptzin 2005). In this previous review, the incidence of postsur-
gical delirium was measured, and there was no clear difference in
the duration of postsurgical delirium between the two groups. In
this current updated review, we focused on the treatment of delir-
ium.We excluded the previous study, Liptzin 2005, because 90 in-
cluded participants did not have delirium at the time of randomi-
sation, and only 15 participants developed delirium after treat-
ment. This current review only included participants with estab-
lished delirium pre-randomisation. Similar to the previous review,
we found no clear difference in the duration of delirium between
the rivastigmine and placebo groups in a non-ICU setting, and no
clear difference between groups for other outcomes such as adverse
events, use of rescue medications, mortality, and leaving the study
early. However, both reviews lacked sufficient evidence to enable
any firm conclusions. Though other meta-analyses have evaluated
the prevention of delirium or treatment efficacy of certain inter-
ventions (Siddiqi 2016; Tampi 2016), participants did not meet
the inclusion criteria of the present review (i.e. they did not have
an established diagnosis of delirium).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Compared with placebo, cholinesterase inhibitors were associated
with no clear benefits or harms in the treatment of delirium due to
a lack of data. There is thus insufficient evidence to support or re-
fute the use of cholinesterase inhibitors for the treatment of delir-
ium in non-intensive care unit (ICU) settings. This conclusion is
consistent with the previous review (Other published versions of
this review).
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Implications for research
One recent review reported that numerous studies investigated the
prevention rather than the treatment of delirium (Siddiqi 2016).
In this current review we also found a paucity of evidence regard-
ing the effect of cholinesterase inhibitors in the treatment of delir-
ium in non-ICU settings, and have identified this area as a priority
for further investigation. Delirium remains a common and serious
condition with no consensus about pharmacological treatment.
More trials are needed with larger sample sizes (for instance 80%
statistical power is warranted) that focus on the treatment of es-
tablished delirium in non-ICU settings. Furthermore, important
outcomes such as the severity of delirium and persistent cognitive
impairment should also be evaluated.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Overshott 2010
Methods Study design: parallel-group, single-centre, randomised controlled trial
Blind: double-blind
Setting: medical wards, the University Hospital of South Manchester NHS Trust,
Manchester, UK
Follow-up: 42 days from the beginning of treatment
Participants Total sample size (at randomisation): n = 15
Diagnostic criteria of delirium: CAM
Age (mean/SD): 84.3/11.2 years in intervention group; 80.6/8.5 years in control group
Sex (male/female): 4/4 in intervention group; 4/3 in control group
Education: not stated
Severity of delirium (assessed by MMSE, mean/SD): 8.6/4.9 in intervention group;
7.4/7.1 in control group
Underlying aetiology of delirium (comorbid illnesses): hypertension (5 participants),
angina (5 participants), stroke (4 participants), atrial fibrillation (4 participants), diabetes
(1 participants)
Baseline comorbid dementia: 3 participants in intervention group, 4 participants in
control group
Inclusion criteria: people over the age of 65 years, identified as having delirium by the
CAM
Exclusion criteria: people were excluded if they were too ill, were taking a cholinesterase
inhibitor, had blood test abnormalities (urea≥ 15mmol/L, or creatinine over 200µmol/
L, or transaminases twice the upper normal limit or a bilirubin level over 40 µmol/L),
had suffered a myocardial infarction, had an unstable cardiac arrhythmia, or had severe
respiratory disease
Interventions 1. Intervention Group: cholinesterase inhibitors, n = 8
Content: participants received rivastigmine tablets.
Dosage/route/frequency: 1.5 mg once a day increasing to 1.5 mg twice a day after 7 days
Treatment duration: the maximum length was 28 days.
2. Control Group: placebo, n = 7
Content: participants received identical placebo tablets.
Dosage/route/frequency: same as above
Treatment duration: same as above
Any concomitant treatments:
If clinicians caring for participants of either group needed to prescribe treatment for
behavioural problems, then this was in accordance with clinically derived protocol for
the management of delirium with chlomethiazole and risperidone
Outcomes 1. Duration of delirium (assessed by CAM, days)
2. Adverse events (nausea)
3. Use of rescue medications (received additional psychotropic medication)
4. Mortality
5. Leaving the study early
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Overshott 2010 (Continued)
Unable to use (not predefined in our protocol): number of participants who assessed
negative by CAM at end of study; number of participants who received antibiotics;
number of discharged participants
Notes The trial was registered with the National Research Ethics Service (reference number:
02/CM/351) and the Clinical Trials Unit at the Department of Health of England and
Wales (reference number: MF 8000/12552)
Conflict of interest declaration: the third author (AB) receives research funding and
consultancy fees from pharmaceutical companies involved in the manufacture and mar-
keting of drugs for Alzheimer’s disease, including Janssen-Cilag, Pfizer, Novartis, Eisai,
Shire, and Lundbeck
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was by numbered
treatment packets by the Department of
Medical Statistics in SouthManchester, in-
dependent of the research team ...” (p.813)
Comments: The investigators described a
random component in the sequence gener-
ation process
Allocation concealment (selection bias) Low risk Quote: “... with the sequence concealed un-
til outcome measures had been completed
for all patients.” (p.813)
Comments: Allocation concealment en-
sured.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “... with the sequence concealed un-
til outcome measures had been completed
for all patients.” (p.813). “The researchers,
who were blind to allocation ...” (p.814)
Comments: Blinding of participants and
personnel ensured.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Each group - treatment or placebo
- was assessed with the CAM daily follow-
ing entry, together with a proforma for ad-
verse events, blind to knowledge of the pa-
tients’ group membership by one of two re-
search nurses.” (p.813)
Comments: Blinding of outcome assess-
ment ensured.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comments: 2 participants withdrew due to
protocol violation.
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Overshott 2010 (Continued)
Selective reporting (reporting bias) Low risk Comments: All outcomes stated in meth-
ods were reported in results
Other bias Low risk Comments: None obvious
CAM: Confusion Assessment Method
MMSE: Mini-Mental State Examination
SD: standard deviation
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Chapin 1977 Study design: not randomised controlled trial
Crowell 1967 Study design: randomised controlled trial
Participants: normal male volunteers
Dautzenberg 2004 Study design: not randomised controlled trial
Doraiswamy 2007 Study design: randomised controlled trial
Participants: not established delirium, people with cognitive decline on at least 1 cognitive domain
EUCTR2007-000262-20-GB Study design: randomised controlled trial
Participants: not established delirium
Fischer 2001 Study design: not randomised controlled trial
Gleason 2003 Study design: not randomised controlled trial
Granacher 1976 Study design: not randomised controlled trial
Heiser 1974 Study design: not randomised controlled trial
Hori 2003 Study design: not randomised controlled trial
Kaufer 1998 Study design: not randomised controlled trial
Lankarani-Fard 2006 Study design: not randomised controlled trial
Liptzin 2005 Study design: randomised controlled trial
Participants: not established delirium
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(Continued)
Listed 2011 Study design: not randomised controlled trial
Marcantonio 2011 Study design: randomised controlled trial
Participants: not established delirium
Moretti 2004 Study design: randomised controlled trial
Participants: not established delirium
Newman 1980 Study design: not randomised controlled trial
NTR 537 Terminated study with no publication
Pitkala 2006 Study design: randomised controlled trial
Participants: delirium
Intervention: intensified, multicomponent geriatric treatment versus usual care, cholinesterase in-
hibitor used in both intervention and control groups
Scicutella 2015 Study design: not randomised controlled trial
Sheldon 2010 Study design: not randomised controlled trial
Silver 2006 Study design: randomised controlled trial
Participants: not established delirium, people with traumatic brain injury
Tenovuo 2009 Study design: randomised controlled trial
Participants: not established delirium, people with traumatic brain injury
Van Eijk 2010 Study design: randomised controlled trial
Participants: intensive care unit patients with delirium
Wengel 1999 Study design: not randomised controlled trial
Youn 2017 Study design: randomised controlled trial
Participants: not established delirium, people with cognitive impairment about to undergo hip
surgery
Zaslavsky 2012 Study design: randomised controlled trial
Participants: not established delirium, people at risk for developing postoperative delirium
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Characteristics of ongoing studies [ordered by study ID]
NCT01487317
Trial name or title A randomized, double-blind, placebo-controlled study of an acetylcholinesterase inhibitor in themanagement
of delirium in hospitalized patients aged 75 years and over
Methods Study design: parallel-group, randomised controlled trial
Blind: double-blind (participant, care provider)
Setting: inpatients
Follow-up: 12 months
Participants Total sample size: n = 23
Inclusion criteria:
• Patients aged 75 and over
• Hospitalisation for delirium not correlated to surgery for less than 48 hours
• Patients with delirium requiring the presence of features 1 (acute onset and fluctuation course), 2
(inattention), 3 (disorganised thinking), and 4 (altered level of consciousness) of the Confusion Assessment
Method and DRS R-98 > 10
• Absence of any contraindications to a cholinesterase inhibitor treatment
• Health insurance affiliation
• Having signed an informed consent form
• Caregiver/informant to provide information on patient
Exclusion criteria:
• Use of cholinesterase inhibitor or memantine medication
• Contraindication to cholinesterase inhibitor medication
• Frontotemporal dementia
• Diseases involving short-term survival
• Digestive bleeding
• Ischaemic and haemorrhagic stroke related to actual onset (including haemorrhagic contusion)
• Natraemia ≤ 120 mmol/L at the time of hospitalisation
• Postepileptic confusion
• Hepatocellular failure
• Cardiorespiratory impairment at risk of transfer to intensive care unit
• Major sensory deficits that could interfere with cognitive assessment (visual and auditory)
• Not fluent in French
• Being under guardianship
• Absence of caregiver/informant to sign informed consent form
Interventions Intervention group: rivastigmine transdermal patch
Content: 1 transdermal patch of rivastigmine (equivalent to 4.6 mg/24 h orally) per day from randomisation
to day 14. Before day 14: end of treatment, if DRS R-98 severity < 10 during 2 consecutive days. At day 14,
if DRS R-98 severity ≥ 10: 1 transdermal patch of rivastigmine 9.5 mg/24 h per day from day 14 to day 30
if DRS R-98 severity < 10, the active treatment will be stopped
Control group: placebo patch
Content: 1 transdermal patch of placebo per day from randomisation to day 14. Before day 14: end of
treatment if DRS R-98 severity < 10 during 2 consecutive days. At day 14 if DRS R-98 severity ≥ 10: 1
transdermal patch of placebo per day from day 14 to day 30 if DRS R-98 severity < 10, the placebo treatment
will be stopped
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NCT01487317 (Continued)
Outcomes • Hospital length of stay from randomisation to declaration by investigator that participant can leave
acute care (maximum of 12 months)
• Percentage of participants with persistent delirium symptoms (DRS R-98 scale; at day 14, day 30)
• Percentage of participants with persistent delirium symptoms at day 30 (CAM scale)
• Percentage of participants with a dementia diagnosis at 12 months
Starting date June 2011
Contact information Marc Verny
Notes The study was completed with no results reported (author contact information was not available)
clinicaltrials.gov/show/NCT01487317
CAM: Confusion Assessment Method
DRS R-98: Delirium Rating Scale-Revised-98
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D A T A A N D A N A L Y S E S
Comparison 1. Cholinesterase inhibitors (rivastigmine) versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Duration of delirium (days) Other data No numeric data
2 Adverse events (nausea) 1 15 Risk Ratio (M-H, Random, 95% CI) 0.30 [0.01, 6.29]
3 Use of rescue medications 1 15 Risk Ratio (M-H, Random, 95% CI) 0.13 [0.01, 2.10]
4 Mortality 1 15 Risk Ratio (M-H, Random, 95% CI) 0.10 [0.01, 1.56]
5 Leaving the study early 1 15 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.07, 11.54]
Analysis 1.1. Comparison 1 Cholinesterase inhibitors (rivastigmine) versus placebo, Outcome 1 Duration of
delirium (days).
Duration of delirium (days)
Study Interventions N MD 95% CI P value
Overshott 2010 Cholinesterase
inhibitors (rivastig-
mine) versus placebo
15 -3.6 -15.6 to 8.4 0.5
Analysis 1.2. Comparison 1 Cholinesterase inhibitors (rivastigmine) versus placebo, Outcome 2 Adverse
events (nausea).
Review: Cholinesterase inhibitors for the treatment of delirium in non-ICU settings
Comparison: 1 Cholinesterase inhibitors (rivastigmine) versus placebo
Outcome: 2 Adverse events (nausea)
Study or subgroup
Cholinesterase
inhibitors
(rivastigmine) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Overshott 2010 0/8 1/7 100.0 % 0.30 [ 0.01, 6.29 ]
Total (95% CI) 8 7 100.0 % 0.30 [ 0.01, 6.29 ]
Total events: 0 (Cholinesterase inhibitors (rivastigmine)), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Cholinesterase inhibitors (rivastigmine) Favours Placebo
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Analysis 1.3. Comparison 1 Cholinesterase inhibitors (rivastigmine) versus placebo, Outcome 3 Use of
rescue medications.
Review: Cholinesterase inhibitors for the treatment of delirium in non-ICU settings
Comparison: 1 Cholinesterase inhibitors (rivastigmine) versus placebo
Outcome: 3 Use of rescue medications
Study or subgroup
Cholinesterase
inhibitors
(rivastigmine) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Overshott 2010 0/8 3/7 100.0 % 0.13 [ 0.01, 2.10 ]
Total (95% CI) 8 7 100.0 % 0.13 [ 0.01, 2.10 ]
Total events: 0 (Cholinesterase inhibitors (rivastigmine)), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Cholinesterase inhibitors (rivastigmine) Favours Placebo
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Analysis 1.4. Comparison 1 Cholinesterase inhibitors (rivastigmine) versus placebo, Outcome 4 Mortality.
Review: Cholinesterase inhibitors for the treatment of delirium in non-ICU settings
Comparison: 1 Cholinesterase inhibitors (rivastigmine) versus placebo
Outcome: 4 Mortality
Study or subgroup
Cholinesterase
inhibitors
(rivastigmine) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Overshott 2010 0/8 4/7 100.0 % 0.10 [ 0.01, 1.56 ]
Total (95% CI) 8 7 100.0 % 0.10 [ 0.01, 1.56 ]
Total events: 0 (Cholinesterase inhibitors (rivastigmine)), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Cholinesterase inhibitors (rivastigmine) Favours Placebo
Analysis 1.5. Comparison 1 Cholinesterase inhibitors (rivastigmine) versus placebo, Outcome 5 Leaving the
study early.
Review: Cholinesterase inhibitors for the treatment of delirium in non-ICU settings
Comparison: 1 Cholinesterase inhibitors (rivastigmine) versus placebo
Outcome: 5 Leaving the study early
Study or subgroup
Cholinesterase
inhibitors
(rivastigmine) Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Overshott 2010 1/8 1/7 100.0 % 0.88 [ 0.07, 11.54 ]
Total (95% CI) 8 7 100.0 % 0.88 [ 0.07, 11.54 ]
Total events: 1 (Cholinesterase inhibitors (rivastigmine)), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Cholinesterase inhibitors (rivastigmine) Favours Placebo
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A P P E N D I C E S
Appendix 1. Sources searched and search strategies
Source Search strategy Hits retrieved
ALOIS (via CRS web)
[Date of most recent search 26 October
2017]
(donepezil OR galantamine OR rivastig-
mine OR tacrine OR E2020 OR aricept*
OR galanthamin* OR nivalin* OR raza-
dyne* OR exelon* OR “SDZ ENA 713”)
AND delirium [health condition]
Dec 2016: 5
Oct 2017: 3
CENTRAL, issue 10 of 12
(The Cochrane Library) http://
crso.cochrane.org/SearchSimple.php
[Date of most recent search 26 October
2017]
#1 MeSH descriptor: [Delirium] this term
only
#2 deliri*
#3 “acute confusion*”
#4 “acute organic psychosyndrome”
#5 “acute brain syndrome”
#6 “metabolic encephalopathy”
#7 “acute psycho-organic syndrome”
#8 “clouded state”
#9 “clouding of consciousness”
#10 “exogenous psychosis”
#11 “toxic psychosis”
#12 “toxic confusion”
#13 obnubilat*
#14 #1 or #2 or #3 or #4 or #5 or #6 or #
7 or #8 or #9 or #10 or #11 or #12 or #13
#15 rivastigmin*
#16 Exelon*
#17 “SDZ ENA 713”
#18 donepezil
#19 rivastigmine
#20 galantamine
#21 tacrine
#22 galanthamine
#23 aricept
#24 E2020
#25 Nivalin
#26 Razadyne
#27 Reminyl
#28 exelon
#29 cognex
#30 #15 or #16 or #17 or #18 or #19 or #
20 or #21 or #22 or #23 or #24 or #25 or
#26 or #27 or #28 or #29
#31 #14 and #30 in Trials
Dec 2016: 27
Oct 2017: 6
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(Continued)
MEDLINE In-process and other non-
indexed citations and MEDLINE 1950-
present (Ovid SP)
[Date of most recent search 26 October
2017]
1. exp Cholinesterase Inhibitors/
2. “cholinesterase inhibitor*”.mp.
3. Galantamine/
4. (galantamine or galanthamine or galant?
amin).mp.
5. (reminyl* orNivalin* or Razadyne*).mp.
6. donepezil.mp.
7. Aricept*.mp.
8. rivastigmine.mp.
9. rivastigmin.mp.
10. Exelon*.mp.
11. exp Tacrine/
12. cognex.mp.
13. or/1-12
14. delir*.mp.
15. confusion.mp.
16. “acute brain failure”.mp.
17. “acute organic psychosyndrome”.mp.
18. “acute brain syndrome”.mp.
19. “metabolic encephalopathy”.mp.
20. “acute psycho-organic syndrome”.mp.
21. “clouded state”.mp.
22. “clouding of consciousness”.mp.
23. “exogenous psychosis”.mp.
24. “toxic psychosis”.mp.
25. “toxic confusion”.mp.
26. exp Delirium/
27. or/14-26
28. 13 and 27
29. randomized controlled trial.pt.
30. controlled clinical trial.pt.
31. randomi?ed.ab.
32. placebo.ab.
33. drug therapy.fs.
34. randomly.ab.
35. trial.ab.
36. groups.ab.
37. or/29-36
38. (animals not (humans and animals)).
sh.
39. 37 not 38
40. 28 and 39
Dec 2016: 238
Oct 2017: 14
EMBASE (Ovid SP)
1974 to 2017 Oct 25
[Date of most recent search 26 October
2017]
1 Delirium/
2 deliri*.mp.
3 “acute confusion*”.ti,ab.
4 “acute organic psychosyndrome”.ti,ab.
5 “acute brain syndrome”.ti,ab.
6 “metabolic encephalopathy”.ti,ab.
Dec 2016: 959
Oct 2017: 110
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7 “acute psycho-organic syndrome”.ti,ab.
8 “clouded state”.ti,ab.
9 “clouding of consciousness”.ti,ab.
10 “exogenous psychosis”.ti,ab.
11 “toxic psychosis”.ti,ab.
12 “toxic confusion”.ti,ab.
13 Delirium, Dementia, Amnestic, Cogni-
tive Disorders/
14 obnubilat*.ti,ab.
15 or/1-14
16 exp Cholinesterase Inhibitors/
17 “cholinesterase inhibitor*”.mp.
18 Galantamine/ 618
19 (galantamine or galanthamine or galant?
amin).mp.
20 (reminyl* or Nivalin* or Razadyne*).
mp.
21 donepezil.mp.
22 Aricept*.mp.
23 rivastigmine.mp.
24 rivastigmin.mp.
25 Exelon*.mp.
26 exp Tacrine/
27 cognex.mp.
28 or/16-27
29 randomized controlled trial/
30 controlled clinical trial/
31 random$.ti,ab.
32 randomization/
33 intermethod comparison/
34 placebo.ti,ab.
35 (compare or compared or comparison).
ti.
36 ((evaluated or evaluate or evaluating or
assessed or assess) and (compare or com-
pared or comparing or comparison)).ab
37 (open adj label).ti,ab. 54779
38 ((double or single or doubly or singly)
adj (blind or blinded or blindly)).ti,ab.
192050
39 double blind procedure/
40 parallel group$1.ti,ab.
41 (crossover or cross over).ti,ab.
42 ((assign$ or match or matched or allo-
cation) adj5 (alternate or group$1 or in-
tervention$1 or patient$1 or subject$1 or
participant$1)).ti,ab
43 (assigned or allocated).ti,ab.
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44 (controlled adj7 (study or design or trial)
).ti,ab.
45 (volunteer or volunteers).ti,ab.
46 trial.ti.
47 or/29-46
48 15 and 28 and 47
PSYCINFO (Ovid SP)
2017 week 3
[Date of most recent search 26 October
2017]
1 Delirium/
2 deliri*.mp.
3 “acute confusion*”.ti,ab.
4 “acute organic psychosyndrome”.ti,ab.
5 “acute brain syndrome”.ti,ab.
6 “metabolic encephalopathy”.ti,ab.
7 “acute psycho-organic syndrome”.ti,ab.
8 “clouded state”.ti,ab.
9 “clouding of consciousness”.ti,ab.
10 “exogenous psychosis”.ti,ab.
11 “toxic psychosis”.ti,ab.
12 “toxic confusion”.ti,ab.
13 obnubilat*.ti,ab.
14 or/1-13
15 exp Cholinesterase Inhibitors/
16 “cholinesterase inhibitor*”.mp.
17 Galantamine/
18 (galantamine or galanthamine or galant?
amin).mp.
19 (reminyl* or Nivalin* or Razadyne*).
mp.
20 donepezil.mp.
21 Aricept*.mp.
22 rivastigmine.mp.
23 rivastigmin.mp.
24 Exelon*.mp.
25 Tacrine.mp.
26 cognex.mp.
27 or/15-26
28 exp Clinical Trials/
29 randomly.ab.
30 randomi?ed.ti,ab.
31 placebo.ti,ab.
32 groups.ab.
33 “double-blind*”.ti,ab.
34 “single-blind*”.ti,ab.
35 RCT.ti,ab.
36 or/28-35
37 14 and 27 and 36
Dec 2016: 23
Oct 2017: 3
CINAHL (EBSCOhost)
[Date of most recent search 26 October
2017]
1 deliri*
2 “acute psycho-organic syndrome” or
“clouded state” or “clouding of conscious-
Dec 2016: 17
Oct 2017: 2
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ness” or “exogenous psychosis” or “toxic
psychosis” or “toxic confusion”
3 “acute brain confusion” or “acute brain
failure” or “acute organic psychosyndrome”
or “acute brain syndrome” or “metabolic
encephalopathy”
4 “Delirium”/
5 S1 OR S2 OR S3 OR S4
6 TX donepezil OR galantamine OR ri-
vastigmine OR tacrine
7 TX aricept* OR E2020
8 S3 TX Galanthamin* OR nivalin* OR
razadyne* OR reminyl*
9 TX exelon* OR “SDZ ENA 713”
10 S6 OR S7 OR S8 OR S9
11 MH “Clinical Trials”
12 TX trial
13 TX “single-blind*”
14 TX “double-blind*”
15 TX “treatment as usual”
16 TX randomly
17 S11 OR S12 OR S13 OR S14 OR S15
OR S16
18 S5 AND S10 AND S17
ISI Web of Science - all databases [in-
cludes: Web of Science (1945-present);
BIOSIS Previews (1926-present); MED-
LINE (1950-present); Journal CitationRe-
ports]
[Date of most recent search 26 October
2017]
TOPIC: (deliri* OR “acute confusion*”
OR “acute organic psychosyndrome” OR
“acute brain syndrome”OR“metabolic en-
cephalopathy” OR “acute psycho-organic
syndrome”OR “clouded state”OR “cloud-
ing of consciousness” OR “exogenous psy-
chosis” OR “toxic psychosis” OR “toxic
confusion” OR obnubilat*) AND TOPIC:
(donepezil OR galantamine OR rivastig-
mine OR tacrine OR E2020 OR aricept*
OR galanthamin* OR nivalin* OR raza-
dyne* OR exelon* OR “SDZ ENA 713”)
AND TOPIC:(randomised OR random-
ized OR randomly or placebo or “double-
blind” or trial OR groups OR “controlled
study” OR RCT OR “single-blind*”)
Timespan: All years.
Search language=Auto
Dec 2016: 78
Oct 2017: 7
LILACS (BIREME)
[Date of most recent search 26 October
2017]
donepezil OR donezepil OR aricept OR
E2020 [Words] or rivastigmine OR ni-
valin OR razadyne OR reminyl OR ex-
elon OR galanthamine OR galantamine
[Words] and deliri$ORdelirioOR loucura
Dec 2016: 0
Oct 2017: 0
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(Continued)
[Words]
ClinicalTrials.gov
(www.clinicaltrials.gov)
[Date of most recent search 26 October
2017]
deliriumOR toxic psychosis OR toxic con-
fusion | donepezil OR rivastigmine OR
galantamine OR tacrine OR galanthamine
OR aricept OR E2020 OR Nivalin OR
Razadyne OR Reminyl OR exelon OR
cognex
Dec 2016: 17
Oct 2017: 0
ICTRP
(http://apps.who.int/trialsearch/)
[Date of most recent search 26 October
2017]
delirium|donepezil OR rivastigmine OR
galantamine OR tacrine OR galanthamine
OR aricept OR E2020 OR Nivalin OR
Razadyne OR Reminyl OR exelon OR
cognex
Dec 2016: 38
Oct 2017: 8
TOTAL before de-duplication 1550
Total after de-duplication 1109
Total after first assessment based on titles and abstracts by CDCIG information specialist 164
C O N T R I B U T I O N S O F A U T H O R S
SW: protocol development, selection of studies and data extraction, drafted parts of the review
ZZ: protocol development, reviewed and drafted parts of the review
TD: content expert, protocol development
SZ: protocol development, reviewed and drafted parts of the review
GP: content expert, protocol development
JX: project management, protocol development, Methodological Expectations of Cochrane Intervention Reviews (MECIR) guidance
AY: protocol development, selection of studies and data extraction, drafted parts of the review
DY: content expert, protocol development
D E C L A R A T I O N S O F I N T E R E S T
SW: none known
ZZ: none known
TD: none known
SZ: none known
GP: none known
JX: none known
AY: none known
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DY: none known
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